Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II (HAE CHAPTER-1)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05047185 |
|
Recruitment Status :
Active, not recruiting
First Posted : September 17, 2021
Last Update Posted : February 21, 2024
|
Sponsor:
Pharvaris Netherlands B.V.
Information provided by (Responsible Party):
Pharvaris Netherlands B.V.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Actual Primary Completion Date : | October 2, 2023 |
| Estimated Study Completion Date : | December 2026 |